NCT00414310View on ClinicalTrials.gov

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Myelodysplastic SyndromeAcute Myelogenous Leukemia
Interventions
DRUG

Decitabine

20 mg/m\^2 IV over 1 hour daily for 5 days.

DRUG

Valproic Acid

50 mg/kg orally daily for 7 days

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00414310 - Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | Biotech Hunter | Biotech Hunter